MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ
23.78
0.00
0.00%
Opening 11:23 07/15 EDT
OPEN
23.62
PREV CLOSE
23.78
HIGH
23.95
LOW
23.20
VOLUME
244.75K
TURNOVER
--
52 WEEK HIGH
25.00
52 WEEK LOW
8.25
MARKET CAP
3.93B
P/E (TTM)
-7.3805
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DYN last week (0706-0710)?
Weekly Report · 2d ago
Insider Move at Dyne Therapeutics Sparks Fresh Investor Buzz
TipRanks · 6d ago
Weekly Report: what happened at DYN last week (0629-0703)?
Weekly Report · 07/06 10:27
Will Barry Greene’s Board Role Shape Dyne Therapeutics’ (DYN) Path From Platform to Products?
Simply Wall St · 07/04 18:24
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
The Motley Fool · 07/04 13:41
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
NASDAQ · 07/01 15:58
Guggenheim Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
TipRanks · 07/01 10:55
Dyne Therapeutics director Jason P. Rhodes disposes of common shares worth $10.66 million
PUBT · 06/30 23:05
More
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.

Webull offers Dyne Therapeutics, Inc stock information, including NASDAQ: DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.